Payment overview · 2025
General Payments
$432.84
21 reported records · 12 companies
Healthcare provider profile · identity verified
Arthur Marush, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1003912809
Verified facts
What the public records show
CMS Open Payments records show Arthur Marush, MD received $432.84 in general payments during 2025 across 21 reported records.
GlaxoSmithKline, LLC. accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Nexletol, Shingrix.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 289 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 289 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $101.55 | 23.5% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $57.90 | 13.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.81 | 13.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.26 | 11.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.19 | 7.4% | 2 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.47 | 5.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.15 | 4.7% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $19.90 | 4.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.95 | 4.4% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $17.35 | 4.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.00 | 3.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.31 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $432.84 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $101.55 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $70.52 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.81 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $48.26 | 2 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 289 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 134 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 31 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
289 | 63 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
289 | 63 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 753 | 207 |
| Losartan Potassium | Losartan Potassium | 578 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 520 | 157 |
| Metoprolol Succinate | Metoprolol Succinate | 456 | 124 |
| Metformin Hcl | Metformin Hcl | 448 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 381 | 111 |
| Simvastatin | Simvastatin | 327 | 96 |
| Eliquis | Apixaban | 289 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 62 |
| Furosemide | Furosemide | 227 | 62 |
| Lisinopril | Lisinopril | 219 | 58 |
| Nifedipine Er | Nifedipine | 180 | 50 |
| Omeprazole | Omeprazole | 177 | 56 |
| Glipizide Er | Glipizide | 166 | 53 |
| Januvia | Sitagliptin Phosphate | 165 | 39 |
| Potassium Chloride | Potassium Chloride | 154 | 46 |
| Atenolol | Atenolol | 153 | 45 |
| Carvedilol | Carvedilol | 153 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 153 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 38 |
| Glipizide | Glipizide | 150 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 147 | 41 |
| Jardiance | Empagliflozin | 134 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 30 |
| Gabapentin | Gabapentin | 107 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 25 |
| Ozempic | Semaglutide | 96 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 22 |
| Metformin Hcl Er | Metformin Hcl | 88 | 29 |
| Enalapril Maleate | Enalapril Maleate | 86 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 86 | 26 |
| Famotidine | Famotidine | 76 | 27 |
| Xarelto | Rivaroxaban | 75 | 17 |
| Valsartan | Valsartan | 71 | 20 |
| Ezetimibe | Ezetimibe | 67 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 20 |
| Allopurinol | Allopurinol | 65 | 21 |
| Terazosin Hcl | Terazosin Hcl | 63 | 19 |
| Montelukast Sodium | Montelukast Sodium | 62 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 36 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Entresto | Sacubitril/Valsartan | 54 | 17 |
| Spironolactone | Spironolactone | 54 | 14 |
| Synthroid | Levothyroxine Sodium | 54 | 14 |
| Colesevelam Hcl | Colesevelam Hcl | 53 | 16 |
| Verapamil Er | Verapamil Hcl | 53 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 14 |
| Finasteride | Finasteride | 45 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 17 |
| Glimepiride | Glimepiride | 43 | suppressed |
| Alprazolam | Alprazolam | 41 | 13 |
| Irbesartan | Irbesartan | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Meloxicam | Meloxicam | 36 | 24 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 35 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | 14 |
| Levemir Flexpen | Insulin Detemir | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | 13 |
| Colchicine | Colchicine | 32 | suppressed |
| Diazepam | Diazepam | 30 | 12 |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Lorazepam | Lorazepam | 29 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Repaglinide | Repaglinide | 28 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Nexletol | Bempedoic Acid | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 19 |
| Metolazone | Metolazone | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Acarbose | Acarbose | 16 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Linzess | Linaclotide | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 13 |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $432.84 · 21 records | GlaxoSmithKline, LLC. | ACCRUFER, Attruby, CAMZYOS, CAPVAXIVE, ELIQUIS, FFRct, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, JARDIANCE, Kerendia, NEXLETOL, SHINGRIX, TRYNGOLZA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error